Interstitial lung disease

References

• Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082. doi:10.1056/NEJMoa1402584.
   PubMed Web of Science ®Google Scholar
• King TE, Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–2092. doi:10.1056/NEJMoa1402582.
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–1769. doi:10.1016/S0140-6736(11)60405-4.
   PubMed Web of Science ®Google Scholar
• Romagnoli M, Colby TV, Suehs CM, et al. Cryobiopsy Compared with Surgical Lung Biopsy in ILD: Reply to Maldonado et al., Froidure et al., Bendstrup et al., Agarwal et al., Richeldi et al., Rajchgot et al., and Quadrelli et al. Am J Respir Crit Care Med. 2019;200(7):944–946. doi:10.1164/rccm.201906-1252LE.
   Web of Science ®Google Scholar
• Troy LK, COLDICE Investigator Team, Grainge C, Corte T, Williamson JP, Vallely MP, Cooper W, et al. Cryobiopsy versus open lung biopsy in the diagnosis of interstitial lung disease (COLDICE): protocol of a multicentre study. BMJ Open Respir Res. 2019;6(1):e000443doi:10.1136/bmjresp-2019-000443.
   Web of Science ®Google Scholar
• Raghu G, Flaherty KR, Lederer DJ, Lynch DA, et al. Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study. Lancet Respir Med. 2019;7(6):487–496. doi:10.1016/S2213-2600(19)30059-1.
   Web of Science ®Google Scholar
• Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518–2528. doi:10.1056/NEJMoa1903076.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718–1727. doi:10.1056/NEJMoa1908681.
   PubMed Web of Science ®Google Scholar
• Maher TM, Corte TJ, Fischer A, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020;8(2):147–157.
   PubMed Web of Science ®Google Scholar
• Guler SA, Ellison K, Algamdi M, et al. Heterogeneity in Unclassifiable Interstitial Lung Disease. A Systematic Review and Meta-Analysis. Annals ATS. 2018;15(7):854–863. doi:10.1513/AnnalsATS.201801-067OC.
   Google Scholar
• Hutchinson JP, McKeever TM, Fogarty AW, et al. Surgical lung biopsy for the diagnosis of interstitial lung disease in England: 1997-2008. Eur Respir J. 2016;48(5):1453–1461. doi:10.1183/13993003.00378-2016.
   PubMed Web of Science ®Google Scholar
• Hutchinson JP, Fogarty AW, McKeever TM, et al. In-Hospital mortality after surgical lung biopsy for interstitial lung disease in the United States. 2000 to 2011. Am J Respir Crit Care Med. 2016;193(10):1161–1167. doi:10.1164/rccm.201508-1632OC.
   PubMed Web of Science ®Google Scholar
• Walsh SLF, Lederer DJ, Ryerson CJ, et al. Diagnostic likelihood thresholds that define a working diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2019;200(9):1146–1153. doi:10.1164/rccm.201903-0493OC.
   PubMed Web of Science ®Google Scholar
• Johannson KA, Marcoux VS, Ronksley PE, et al. Diagnostic yield and complications of transbronchial lung cryobiopsy for interstitial lung disease. A systematic review and metaanalysis. Ann Am Thorac Soc. 2016;13(10):1828–1838. doi:10.1513/AnnalsATS.201606-461SR.
   PubMed Web of Science ®Google Scholar
• Johannson KA, Kolb M, Fell CD, et al. Evaluation of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society position statement. Can J Respir Criti Care & Sleep Med. 2017;1(3):133–141.
   Web of Science ®Google Scholar
• Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708–719. doi:10.1016/S2213-2600(16)30152-7.
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med. 2018;378(1):35–47. doi:10.1056/NEJMoa1703327.
   PubMed Web of Science ®Google Scholar